Table 3.

Proportion of patients with both HbA1c and body weight reduction at Weeks 52 and 104

	GLIM (n = 474)	CANA 100 mg (n = 478)	CANA 300 mg (n = 474)
Week 52
Patients, n (%)	127 (26.8)	346 (72.4)	372 (78.5)
Difference vs GLIM (95% CI)		45.6 (39.7, 51.5)	51.7 (46.0, 57.3)
OR vs GLIM (95% CI)		7.7 (5.7, 10.3)	10.7 (7.9, 14.5)
Week 104
Patients, n (%)	127 (26.8)	313 (65.5)	337 (71.1)
Difference vs GLIM (95% CI)		38.7 (32.6, 44.7)	44.3 (38.4, 50.2)
OR vs GLIM (95% CI)		5.6 (4.2, 7.5)	7.4 (5.5, 9.8)

CANA canagliflozin, CI confidence interval, GLIM glimepiride, OR odds ratio